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95 ANALYSIS OF SYNOVIAL FLUID BIOMARKERS IN PATIENTS
WITH RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, AND
NORMAL DONORS
R. Kokebie1, A. Yanke1, A.A. Hakimiyan1, M. Michalska1, D.C. Rueger2,
J.A. Block1, S. Chubinskaya1. 1Rush University Medical Center,
Chicago, IL, USA, 2Stryker Biotech, Hopkinton, MA, USA
Purpose: To compare synovial ﬂuid (SF) biomarker levels in samples
from patients with rheumatoid (RA), osteoarthritis (OA), and normal organ
donors for prognostic/diagnostic purposes.
Methods: Synovial ﬂuid (SF) was collected from the knees of 45 (6 males
and 39 females) OA, 22 (14 females and 8 males) RA patients and 20
(15 females and 5 males) normal organ donors. Eight biomarkers ana-
lyzed by ELISA methods were evaluated: interleukin (IL)-1, Il-6, Il-8, Il-11,
leukemia inﬂammatory factor (LIF), cartilage oligomeric protein (COMP),
osteocalcin, and osteogenic protein-1 (OP-1). Multivariate analysis as-
sessed the effects of gender and disease activity: WOMAC scores for OA
samples, and SF WBC, ESR, CRP for RA samples. Multivariant Kruskal-
Wallis and Mann-Whitney Tests were used; p< 0.05 was considered
signiﬁcant.
Results: The mean (±SD) age was: 53±9 years for OA, 54±11 for RA,
and 52±7 for donors. No gender differences were identiﬁed between
markers. In RA SF, the levels of 4 out of 5 tested cytokines/chemokines
were higher than in OA and normal SF. The most signiﬁcant differences
were found for Il-6 and Il-8, where Il-6 concentration was 2.5-fold higher
than in OA, 2587.59±6393.69 vs. 1045.68±5451.13 øg/ml, respectively
(p< 0.005), and 8-fold higher than in normal, 2587.59±6393.69 vs.
339.06±906.28, respectively (P< 0.002). The levels of Il-8 were 8-fold
higher than in OA, 6490.04±16550.74 vs 849.48 øg/ml, respectively
(P< 0.0005) and normal, 6490.04±16550.74 vs 788.69±837.705 øg/ml,
respectively (P< 0.028). The differences for Il-11 were not as substantial,
especially between RA and OA samples, while it was a 5-fold differ-
ence between OA and normal SF, 654.11±1411.844 øg/ml, respectively
(P< 0.003). The value of Il-1 was signiﬁcantly higher in normal than OA,
9.81±2.72 vs 8.56±7.06 øg/ml, respectively (P< 0.004); in the RA, it was
a tendency for a higher concentration of Il-1 than in OA and normal, but it
did not reach signiﬁcance. Surprisingly, concentration of LIF was higher in
normal samples than in RA (P< 0.044) and OA (P< 0.001). The highest
levels of OP-1 were found in normal SF (541.92±28.61 ng/ml), which
were almost 5-fold higher than in OA (112.40±124.64) (P< 0.001) and
more than 2-fold higher than in RA SF (202.25±149.13 ng/ml, P< 0.001).
No differences were detected in the levels of COMP or osteocalcin
between the experimental groups. Although the differences between
active and inactive states of OA or RA were insigniﬁcant, for cytokines and
OP-1 each state was statistically different from normal. SF from both OA
and RA had higher biomarker levels than normals, regardless of disease
state, though there was a trend of higher chemokine levels in less active
RA, and higher Il-1, Il-6, and Il-8 levels in active OA.
Conclusions: Our ﬁndings suggest that the levels of pathophysiologically
important biomarkers in SF of patients with OA and RA differ according
to the mechanisms that drive each disease. Thus, Il-1, Il-11, LIF and
OP-1 appear to be signiﬁcant for OA; while Il-6, Il-8, and OP-1 may have
signiﬁcance for RA. As previously observed in cartilage, a strong negative
correlation between the levels of OP-1 and Il-6 family of chemokines was
seen. Larger studies are necessary to develop a biomarker algorithm that
would be of diagnostic/prognostic use.
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Purpose: Osteoarthritis (OA) is a multifactorial disease, the causes of
which remain contentious. The studies presented were designed to seek
evidence of vascular abnormalities in OA. These ﬁndings led to the formu-
lation of a “Vascular Concept of OA Causation” that incorporates currently
known laboratory, clinical and epidemiological data. This concept has
signiﬁcant implications for our approach to OA detection and treatment
and has been used to develop a rudimentary approach to early OA
detection.
Methods: Histological studies: Femoral heads removed from 11 OA
patients at hip arthroplasty were examined histologically for evidence of
microvascular thrombosis and occlusive intravascular lipid. They were
compared with seven control femoral heads obtained at post mortem
from donors in whom OA was excluded.
Haematological studies: Global and speciﬁc markers of coagulability,
ﬁbrinolysis, inﬂammation, matrix degradation and bone turnover were
measured in peripheral blood from 44 patients with OA of the hip and
52 control subjects.
Use of combinations of “markers” to detect OA: A subset of 12 potential
haematological markers and clinical measures was reﬁned and applied
to 45 subjects with OA and 47 control subjects to determine if the number
of markers per subject could be used as a guide to discriminate between
OA and non-OA subjects.
Results: Histological studies conﬁrmed the presence of occlusive in-
travascular lipid and thrombosis in the vessels of the femoral head of
patients with OA. These changes were not observed in the control femoral
heads. The haematological studies and clinical data showed increased
procoagulant tendency in OA with signiﬁcantly increased blood pressure,
BMI, blood lipids, platelet aggregation, clotting factors, blood viscosity and
ﬁbrinopeptide A levels. There was hypoﬁbrinolysis as shown by prolonged
euglobulin clot lysis time and raised plasminogen activator inhibitor, alpha
2 antiplasmin and LP(a) levels. Mild inﬂammation was demonstrated with
increased levels of Il-1, TNF alpha and CRP. Leukocyte elastase degrades
collagen and elastic ﬁbres and it was elevated in OA. There were also
increased levels of markers of bone turnover including ALP, BGP and DPD
crosslinks. All parameters were statistically signiﬁcant. Seventy percent
of OA patients had four or more markers versus only 15% of controls and
there was generally a combination of both increased coagulation risk and
hypoﬁbrinolysis in the osteoarthritis subjects.
These ﬁndings led to the formulation of a “Vascular Concept of OA Causa-
tion” that links vascular insufﬁciency to the clinical and laboratory ﬁndings
in OA. Based on this we propose that anti-arthritic agents that act on
the actual disease processes ought to enhance the joint microcirculation
and in addition to being anti-inﬂammatory they should also have core
activities that include anti-coagulant, ﬁbrinolytic and lipolytic activities that
will promote haemostasis.
Conclusions: Mounting evidence supports a key role for impaired blood
ﬂow in the initiation and progression of OA. Recognising the important
role of vascular insufﬁciency in OA creates new insights that could
lead to the early detection of OA. By expanding our focus to include
vascular abnormalities together with inﬂammation, this new perspective
can lead to the development of novel therapeutic targets for OA and more
comprehensive approaches to treatment that have the potential to slow
or halt the disease process. This concept also provides a rationale for
some of the strengths and inadequacies of current pharmacological and
complementary anti-arthritic medicines.
97 IS SERUM TRANSFORMING GROWTH FACTOR-BETA (TGF-b)
A BIOMARKER OF RADIOGRAPHIC OSTEOARTHRITIS (rOA)
AT THE KNEE AND HIP?
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Purpose: We have observed that African Americans (AA) are more likely
to have osteophytes at the hip and knee compared to Whites. Elevated
TGF-b has been associated with osteophyte formation in the OA joint.
Therefore, the purpose of the current study was to assess the utility of
serum TGF-b as a biomarker of rOA in AAs and Whites, men and women,
with and without hip and knee rOA.
Methods: Baseline data from 330 participants (42% AA; 39% men) in the
Johnston County Osteoarthritis Project Biomarker Substudy were used in
the analysis. Natural logarithm transformation was used to produce near-
normal distributions for TGF-b (lnTGF-b) in analyses. Descriptive statistics
were calculated for demographic variables, knee and hip rOA (deﬁned as
K/L grade  2 at each joint), and lnTGF-b; differences were assessed
by two-sample t-tests. Generalized linear models were used to obtain
least squared means estimates for lnTGF-b and rOA presence, laterality
(none, unilateral, or bilateral), and severity (K/L grade 0, 1 = none, K/L
grade 2=mild, K/L grade 3, 4 =moderate/severe). Models were adjusted
for age, gender, race, and body mass index (BMI). Interactions by race
and gender were considered signiﬁcant at a p-value <0.1. Analyses were
performed using SAS version 9.1 (Cary, NC).
Results: The mean age of the sample was 60.5±9.4 years, with a
mean BMI of 30.3±6.9 kg/m2; 54% had knee rOA and 22% had hip rOA.
The mean for lnTGF-b was 2.82±0.34 ng/mL. Mean lnTGF-b was higher
among AA participants compared to Whites (p = 0.0085), and women
compared to men (p = 0.0006). There were no signiﬁcant associations
